
    
      Disruption of the intestinal epithelial barrier is part of the pathophysiology of IBS
      favoring immune activation present in the mucosa of these patients and the development of
      symptoms in IBS. To evaluate the effect of treatment with pentoxifylline (PTX) in patients
      with IBS related to clinical response and modulation of the components of the epithelial
      barrier at the level of intestinal mucosa.
    
  